Expression of PCNA, CD-31 and HER-2 in Serbian patients with oral squamous cell carcinoma



oral carcinoma, squamous cell carcinoma, tumor markers, PCNA, CD-31, HER-2


Paper description:

  • Tumor markers are significant for early detection of (pre)malignant lesions, local recurrence and distant metastasis, prevention of secondary tumors, appropriate therapeutic protocol choice, and as a prognostic factor for disease progression.
  • In this prospective case, immunohistochemical expression of the tumor markers PCNA, HER-2 and CD-31 in patients with oral squamous cell carcinoma undergoing the same surgical treatment during a ten years period was determined.
  • Increased expression of PCNA during advanced stage of the disease may be a useful biomarker in determining further disease progression. PCNA can be useful in routine clinical practice.

Abstract: Several studies have investigated the expression of tumor markers, including p53, HER-2, PCNA, EGFR, VEGFR CD-31 and Bcl-2 in patients with oral squamous carcinoma (OSC). This study aimed to determine the expression of proliferating cell nuclear antigen (PCNA), endothelial functions of platelet/endothelial cell adhesion molecule-1 (CD31) and human epidermal growth factor receptor-2 (HER-2) according to OSC stage. The prospective study included 62 patients diagnosed with OSC stages II and III. Surgical specimens were obtained from tumor and peritumoral tissues. We determined the pathohistological degree of tumor differentiation and the immunohistochemical expression of PCNA, CD-31 and HER-2 for each specimen. Immunohistochemical analysis of the expression of PCNA in tumor cells demonstrated poor staining of immunoreactive tumor cells in 23 patients (10 in stage II, 7 in stage IIIa and 6 in stage IIIb). Moderately expressed PCNA-immunoreactivity in the tumor cells in 17 patients (7 in stage II, 6 in stage IIIa and 4 in stage III), and extremely strong PCNA-immunoreactive staining in tumor cells of 10 patients with IIIb stage, was observed. These results suggest that PCNA expression combined with pathohistological findings could possess a prognostic value in determining the survival rates for patients with oral squamous cell carcinoma.

Received: July 5, 2019; Revised: August 4, 2019; Accepted: August 6, 2019; Published online: August 30, 2019

How to cite this article: Lončarević SA, Brajković DO, Gardašević MF, Lončarević OLj, Lađević NG, Nešić DM, Stamenković DM, Likić-Lađević IS, Lađević NN, Rančić NK. Expression of PCNA, CD-31 and HER-2 in Serbian patients with oral squamous cell carcinoma. Arch Biol Sci. 2019;71(4):703-10.


Download data is not yet available.

Author Biographies

Milka F. Gardašević, Clinic for Maxillofacial Surgery, Military Medical Academy, Belgrade

Dušica M. Stamenković, 1. Department of Anesthesiology and Intensive Care, Military Medical Academy, Belgrade; 2. Medical Faculty Military Medical Academy, University of Defense, Belgrade

Nemanja K. Rančić, 1. Medical Faculty Military Medical Academy, University of Defense, Belgrade; 2. Centre for Clinical Pharmacology, Military Medical Academy, Belgrade; 3. Institute of Radiology, Military Medical Academy, Belgrade


Martínez-Lara I, González-Moles MA, Ruiz-Avila I, Bravo M, Ramos MC, Fernández-Martínez JA. Proliferating cell nuclear antigen (PCNA) as a marker of dysplasia in oral mucosa. Acta Stomatol Belg. 1996;93(1):29-32.

Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. Int J Cancer. 2001;94(2):153-6.

World Health Organization. International Agency for Research on Cancer. Lip, oral cavity. In: The Global Cancer Observatory. Cancer Today, Database. [last updated 2018 Mar; cited 2019 Jul 25]. Available from:

Wang B, Zhang S, Yue K, Wang XD. The recurrence and survival of oral squamous cell carcinoma: a report of 275 cases. Chin J Cancer. 2013;32(11):614-8.

Tonchev K, Vladimirov B. Survival rates in oral cancer patients - a 10-year retrospective study. J IMAB. 2016;22(4):1385-8.

Listl S, Jansen L, Stenzinger A, Freier K, Emrich K, Holleczek B, Katalinic A, Gondos A, Brenner H; GEKID Cancer Survival Working Group. Survival of patients with oral cavity cancer in Germany. PLoS One. 2013;8(1):e53415.

Loncarević S, Vignjević S, Jović N, Aćimović L, Gardasević M, Todorović V, Dimitrijević J. Significance of pathohistological findings and the expression of Bcl-2 in diagnosis and treatment of oral planocellular carcinoma. Vojnosanit Pregl. 2012;69(4):314-9.

Fuchs A, Hartmann S, Ernestus K, Mutzbauer G, Linz C, Brands RC, Kübler AC, Müller-Richter UD. Mandibular intraosseous pseudocarcinomatous hyperplasia: a case report. J Med Case Rep. 2016;10(1):268.

Dimitrijević J. Clinical pathology. Srp Arh Celok Lek. 2006;134(Suppl 1):78-83.

Wilson GD, Saunders MI, Dische S, Richman PI, Daley FM, Bentzen SM. Bcl-2 expression in head and neck cancer: an enigmatic prognostic marker. Int J Radiat Oncol Biol Phys. 2001;49(2):435-41.

Rodrigo JP, Coto E, González MV, Maldonado M, Suárez C. P53 allelic loss and outcome in patients with squamous cell carcinoma of the head and neck. Eur Arch Otorhinolaryngol. 2001;258(5):255-8.

Monteiro LS, Diniz-Freitas M, Garcia-Caballero T, Forteza J, Fraga M. EGFR, and Ki-67 expression in oral squamous cell carcinoma using tissue microarray technology. J Oral Pathol Med. 2010;39(7):571-8.

Choontharu MM, Binda A, Bhat S, Sharma SM. Role of tumor markers in oral squamous cell carcinoma: Review of literature and future consideration. SRM J Res Dental Sci. 2012;3(4):251-6.

Scully C, Sudbø J, Speight PM. Progress in determining the malignant potential of oral lesions. J Oral Pathol Med. 2003;32(5):251-6.

Kurki P, Ogata K, Tan EM. Monoclonal antibodies to proliferating cell nuclear antigen (PCNA)/cyclin as probes for proliferating cells by immunofluorescence microscopy and flow cytometry. J Immunol Methods. 1988;109(1):49-59.

Chiang CP, Lang MJ, Liu BY, Wang JT, Leu JS, Hahn LJ, Kuo MY. Expression of proliferating cell nuclear antigen (PCNA) in oral submucous fibrosis, oral epithelial hyperkeratosis, and oral epithelial dysplasia in Taiwan. Oral Oncol. 2000;36(4):353-9.

Srinivasan M, Jewell SD. Quantitative estimation of PCNA, c-myc, EGFR and TGF-alpha in oral submucous fibrosis - an immunohistochemical study. Oral Oncol. 2001;37(5):461-7.

Shahela T, Aesha S, Ranganathan K, T R, Roa K UD, Joshua E, Ahmed AS, Chittamsetty H. Immunohistochemical Expression of PCNA in Epithelial Linings of Selected Odontogenic Lesions. J Clin Diagn Res. 2013;7(11):2615-8.

Keshav R, Narayanappa U. Expression of Proliferating Cell Nuclear Antigen (PCNA) in Oral Submucous Fibrosis: An Immunohistochemical Study. J Clin Diagn Res. 2015;9(5): ZC20-3.

Jaafari Ashkavandi Z, Moshref M, Mashhadi-Abbas F, Sargolzaie S, Taghavi N. Evaluation of CD31 Expression and Mast Cell Count in Dysplastic Lesions and Squamous Cell Carcinoma of the Oral Cavity. IRCMJ. 2010;12(3):272-6.

Papavasileiou D, Tosios K, Christopoulos P, Goutas N, Vlachodimitropoulos D. Her-2 immunohistochemical expression in oral squamous cell carcinomas is associated with polysomy of chromosome 17, not Her-2 amplification. Head Neck Pathol. 2009;3(4):263-70.

Hanken H, Gaudin R, Gröbe A, Fraederich M, Eichhorn W, Smeets R, Simon R, Sauter G, Grupp K, Izbicki JR, Sehner S, Heiland M, Blessmann M. Her2 expression and gene amplification is rarely detectable in patients with oral squamous cell carcinomas. J Oral Pathol Med. 2014;43(4):304-8.

Lo Muzio L, Santarelli A, Panzarella V, Campisi G, Carella M, Ciavarella D, Di Cosola M, Giannone N, Bascones A. Oral squamous cell carcinoma and biological markers: an update on the molecules mainly involved in oral carcinogenesis. Minerva Stomatol. 2007;56(6):341-7.

Smilek P, Dusek L, Veselý K, Rottenberg J, Kostrica R. Prognostic significance of mitotic and apoptotic index and the DNA cytometry in head and neck cancer. Neoplasma. 2005;52(3):199-207.

Amin MB, Greene FL, Edge SB, Compton CC, Gershenwald JE, Brookland RK, Meyer L, Gress DM, Byrd DR, Winchester DP. The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more "personalized" approach to cancer staging. CA Cancer J Clin. 2017;67(2): 93-9.

Amin MB, Edge S, Greene F, Byrd DR, Brookland RK, Washington MK, Gershenwald JE, Compton CC, Hess KR, Sullivan DC, Jessup JM, Brierley JD, Gaspar LE, Schilsky RL, Balch CM, Winchester DP, Asare EA, Madera M, Gress DM, Meyer LR, editors. AJCC Cancer Staging Manual. 8th ed. New York, NY: Springer International Publishing; 2017.

Wang LH, Wu CF, Rajasekaran N, Shin YK. Loss of Tumor Suppressor Gene Function in Human Cancer: An Overview. Cell Physiol Biochem. 2018;51(6):2647-93.

Ali J, Sabiha B, Jan HU, Haider SA, Khan AA, Ali SS. Genetic etiology of oral cancer. Oral Oncol. 2017;70:23-8.

Sugerman PB, Joseph BK, Savage NW. The role of oncogenes, tumor suppressor genes, and growth factors in oral squamous cell carcinoma: a case of apoptosis versus proliferation. Oral Dis. 1995;1(3):172-88.

Papavasileiou D, Tosios K, Christopoulos P, Goutas N, Vlachodimitropoulos D. Her-2 immunohistochemical expression in oral squamous cell carcinomas is associated with polysomy of chromosome 17, not Her-2 amplification. Head Neck Pathol. 2009;3(4):263-70.

Lopes MA, Nikitakis NG, Reynolds MA, Ord RA, Sauk J Jr. Biomarkers predictive of lymph node metastases in oral squamous cell carcinoma. J Oral Maxillofac Surg. 2002;60(2):142-147.

Ribeiro-Silva LROA. Prognostic significance of immunohistochemical biomarkers in oral squamous cell carcinoma. Int J Oral Maxillofac Surg. 2011;40(3):298-307.

Khan H, Gupta S, Husain N, Misra S, Mps N, Jamal N, Ghatak A. Correlation between expressions of Cyclin-D1, EGFR and p53 with chemoradiation response in patients of locally advanced oral squamous cell carcinoma. BBA Clin. 2015;3:11-7.

Lothaire P, de Azambuja E, Dequanter D, Lalami Y, Sotiriou C, Andry G, Castro G Jr, Awada A. Molecular markers of head and neck squamous cell carcinoma: promising signs in need of prospective evaluation. Head Neck. 2006;28(3):256-69.

Lallemant B, Evrard A, Chambon G, Sabra O, Kacha S, Lallemant JG, Lumbroso S, Brouillet JP. Gene expression profiling in head and neck squamous cell carcinoma: Clinical Perspectives. Head Neck. 2010;32(12):1712-9.

Yuen AP, Lam KY, Choy JT, Ho WK, Wong LY, Wei WI. Clinicopathologic significance of Bcl-2 expression in the surgical treatment of oral tongue carcinoma. Eur J Surg Oncol. 2002;28(6):667-72.

Baba AI, Câtoi C. Comparative Oncology. Bucharest: The Publishing House of the Romanian Academy; 2007.

Fischer AH, Zhao C, Li QK, Gustafson KS, Eltoum IE, Tambouret R, Benstein B, Savaloja LC, Kulesza P. The cytologic criteria of malignancy. J Cell Biochem. 2010;110(4):795-811.

Chen J, Wu M, Liu R, Li S, Gao R, Song B. Preoperative evaluation of the histological grade of hepatocellular carcinoma with diffusion-weighted imaging: a meta-analysis. PLoS One. 2015;10(2):e0117661.

Sung WW, Lin YM, Wu PR, Yen HH, Lai HW, Su TC, Huang RH, Wen CK, Chen CY, Chen CJ1, Yeh KT. High nuclear/cytoplasmic ratio of Cdk1 expression predicts poor prognosis in colorectal cancer patients. BMC Cancer. 2014;14:951.

Golubović M, Asanin B, Jelovac D, Petrović M, Antunović M. Correlation between disease progression and histopathologic criterions of the lip squamous cell carcinoma. Vojnosanit Pregl. 2010;67(1):19-24.

Brusevold IJ, Søland TM, Khuu C, Christoffersen T, Bryne M. Nuclear and cytoplasmic expression of Met in oral squamous cell carcinoma and an organotypic oral cancer model. Eur J Oral Sci. 2010;118(4):342-9.

Poosarla C, Ramesh M, Ramesh K, Gudiseva S, Bala S, Sundar M. Proliferating Cell Nuclear Antigen in Premalignancy and Oral Squamous Cell Carcinoma. J Clin Diagn Res. 2015;9(6):ZC39-41.

Lan HA, Zain RB, Saitoh M, Muramatsu Y, Shrestha P, Mori M. Proliferating cell nuclear antigen (PCNA) and p53 in epithelial dysplasia and squamous cell carcinoma of oral mucosa--a marker for poor tumor differentiation, increasing nuclear atypia and invasiveness? Anticancer Res. 1996;16(5B):3059-65.

Broćić M, Kozomara R, Cerović S, Jović N, Vukelić-Marković S, Stosić S. Clinical significance of vascular endothelial growth factor expression in patients with carcinoma of the mouth floor and tongue. Vojnosanit Pregl. 2009;66(6):440-8.

Motta Rda R, Zettler CG, Cambruzzi E, Jotz GP, Berni RB. Ki-67 and p53 correlation prognostic value in squamous cell carcinomas of the oral cavity and tongue. Braz J Otorhinolaryngol. 2009;75(4):544-9.

Tsuji T, Sasaki K, Kimura Y, Yamada K, Mori M, Shinozaki F. Measurement of proliferating cell nuclear antigen (PCNA) and its clinical application in oral cancers. Int J Oral Maxillofac Surg. 1992;21(6):369-72.

Steinbeck RG, Moege J, Heselmeyer KM, Klebe W, Neugebauer W, Borg B, Auer GU. DNA content and PCNA immunoreactivity in oral precancerous and cancerous lesions. Eur J Cancer B Oral Oncol. 1993;29B(4):279-84.

Al-Azzawi Lehadh M. Immunohistochemical Analysis of PCNA and P53 Proteins in Oral Lichen Planus, Oral Dysplasia and Normal Oral Mucosa. Diyala J Med. 2014;6(1):41-7.

Pahuja S, Choudhury M, Gupta U. Ki-67 immunostaining in Pap smears of cervix: assessment of proliferation in preinvasive and invasive squamous epithelial lesions. Indian J Pathol Microbiol. 2004;47(1):1-3.

Heatley MK. What is the value of proliferation markers in the normal and neoplastic cervix? Histol Histopathol. 1998;13(1):249-54.

Srivastava S. P16INK4A and MIB-1: An immunohistochemical expression in preneoplasia and neoplasia of the cervix. Indian J Pathol Microbiol. 2010;533(3):518-24.

Goel MM, Mehrotra A. Immunohistochemical expression of MIB-1 and PCNA in precancerous and cancerous lesions of uterine cervix. Indian J Cancer. 2013;50(3):200-5.

Wan Y, Wu X. Expressions of PCNA and EMMPRIN in esophageal squamous cell carcinoma and their clinical significance. Tumor. 2011;31(2):141-4.

Bernardes VF, Gleber-Netto FO, Sousa SF, Silva TA, Aguiar MC. Clinical significance of EGFR, Her-2 and EGF in oral squamous cell carcinoma: a case control study. J Exp Clin Cancer Res. 2010;29:40.

Chen IH, Chang JT, Liao CT, Wang HM, Hsieh LL, Cheng AJ. Prognostic significance of EGFR and Her-2 in oral cavity cancer in betel quid prevalent area cancer prognosis. Br J Cancer. 2003;89(4):681-6.

Fukumitsu R, Takagi Y, Yoshida K, Miyamoto S. Endoglin (CD105) is a more appropriate marker than CD31 for detecting microvessels in carotid artery plaques. Surg Neurol Int. 2013;4:132.

Ingaleshwar PS, Pandit S, Desai D, Redder CP, Shetty AS, Mithun KM. Immunohistochemical analysis of angiogenesis by CD34 and mast cells by toluidine blue in different grades of oral squamous cell carcinoma. J Oral Maxillofac Pathol. 2016;20(3):467-73.

Li SH, Hung PH, Chou KC, Hsieh SH, Shieh YS. Tumor angiogenesis in oral squamous cell carcinomas: The significance of endothelial markers and hotspot selection. J Med Sci. 2009;29:67-74.




How to Cite

Lončarević SA, Brajković DO, Gardašević MF, Lončarević OL, Lađević NG, Nešić DM, Stamenković DM, Likić-Lađević IS, Lađević NN, Rančić NK. Expression of PCNA, CD-31 and HER-2 in Serbian patients with oral squamous cell carcinoma. Arch Biol Sci [Internet]. 2019Dec.19 [cited 2022Aug.18];71(4):703-10. Available from:




Most read articles by the same author(s)